Jytaglen (Sitagliptin)

Sitagliptin works by selectively inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition prevents the breakdown of the incretin hormones GLP‑1 and GIP, leading to higher circulating levels of these hormones. Elevated incretins increase glucose‑dependent insulin secretion from pancreatic β‑cells and suppress glucagon release from α‑cells, thereby reducing blood glucose concentrations.

The appropriate dose of Jytaglen is determined by the prescribing healthcare professional based on the individual’s renal function, concomitant medications and overall treatment plan. Dosage adjustments may be required for patients with impaired kidney function, and the prescriber will select the tablet strength and frequency that best fits the patient’s needs.

Safety data for sitagliptin in pregnancy and lactation are limited, and the drug is generally not recommended unless the potential benefit outweighs the risk. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatment options with their healthcare provider.

To place an order, submit an enquiry on the Jytaglen product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other oral antidiabetic classes, sitagliptin offers glucose‑dependent insulin secretion without causing weight gain, a common issue with sulfonylureas. Unlike metformin, it is less likely to cause gastrointestinal upset, but it does not have the same cardiovascular benefits demonstrated for some newer agents such as SGLT‑2 inhibitors. Choice of therapy depends on individual patient factors.

Jytaglen tablets should be stored at room temperature, below 25 °C (77 °F). Keep the medication in its original blister pack or container, protect it from moisture, heat and direct sunlight, and ensure that it is out of reach of children. Do not use the product after the expiration date printed on the packaging.

Jytaglen is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed. Consistency in the timing of each dose helps maintain stable blood glucose control, and patients should follow any additional instructions regarding diet and exercise.

The most serious adverse reactions reported with sitagliptin include pancreatitis, severe hypersensitivity reactions such as anaphylaxis, and rare cases of hepatic injury. Patients should be advised to seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or signs of liver dysfunction. Monitoring for these events is especially important when the drug is used with other glucose‑lowering agents.

Jytaglen is contraindicated in patients with a known hypersensitivity to sitagliptin or any of the tablet’s excipients. It should be used with caution, or avoided, in individuals with severe renal impairment, a history of pancreatitis, or those taking concomitant medications that may increase the risk of hypoglycemia. Pregnant or nursing women should only use it if clearly prescribed by a qualified clinician after evaluating risks and benefits.